Apis Capital Advisors’s Viking Therapeutics VKTX Stock Holding History

Apis Capital Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-116,506	Closed	-$3.09M	–	65
2025 Q2	$3.09M	Buy	116,506 +4,506	+4%	+$119K	1.1%	23
2025 Q1	$2.7M	Buy	112,000 +16,000	+17%	+$506K	1.31%	23
2024 Q4	$3.86M	Buy	96,000 +19,000	+25%	+$1.08M	2.57%	12
2024 Q3	$4.87M	Sell	77,000 -23,000	-23%	-$1.35M	3.39%	9
2024 Q2	$5.3M	Buy	100,000 +30,000	+43%	+$1.97M	3.91%	9
2024 Q1	$5.74M	Sell	70,000 -20,000	-22%	-$890K	4.36%	5
2023 Q4	$1.67M	Sell	90,000 -58,000	-39%	-$759K	1.76%	20
2023 Q3	$1.64M	Buy	+148,000	New	+$2.12M	2.12%	11
2019 Q3	$619K	Sell	90,000 -43,000	-32%	-$319K	0.97%	22
2019 Q2	$1.1M	Sell	133,000 -17,000	-11%	-$145K	1.65%	17
2019 Q1	$1.49M	Buy	150,000 +30,000	+25%	+$251K	1.8%	12
2018 Q4	$918K	Buy	+120,000	New	+$1.43M	1.23%	20

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Apis Capital Advisors's VKTX Position: Q3 2025 in Review

Apis Capital Advisors sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 116,506 shares — an estimated $3.09M sold.

Apis Capital Advisors first reported a position in VKTX in Q4 2018 and held it in 12 quarters. The position peaked at $5.74M in Q1 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Apis Capital Advisors reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
Apis Capital Advisors sold 116,506 Viking Therapeutics shares in Q3 2025, an estimated $3.09M.
Apis Capital Advisors first reported a position in Viking Therapeutics in Q4 2018 and held it in 12 quarters.
Apis Capital Advisors's Viking Therapeutics position peaked at $5.74M in Q1 2024.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Apis Capital Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.